{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001685","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.779072+00:00","generated_at":"2026-05-28T05:24:10.511167+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lantern Pharma amends CSO Bhatia's agreement: term to Jan 2026, reduced hours, $189,600 salary","bullets":["Kishor G. Bhatia, CSO, employment term extended to January 15, 2026.","Minimum weekly hours reduced to 24 for scientific, clinical, and therapeutic development.","Annual base salary proportionately adjusted to $189,600 effective first pay period January 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001685","json":"https://secwatch.observer/filing/0001493152-25-001685.json","markdown":"https://secwatch.observer/filing/0001493152-25-001685.md","text":"https://secwatch.observer/filing/0001493152-25-001685.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225001685/0001493152-25-001685-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225001685/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:24:10.511167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}